国产精品女人呻吟在线观看_蜜桃无码一区二区三区_亚区产品A级乱码_国产AV巨作情欲放纵无码 五色视频精品全部免费-1769国产精品短视频-精品一区二区三区亚洲-91精品国产福利在线观看

About Us

Core Team

An experienced and efficient international team from China and the United States.
  1. Dr. Hongqi Tian

    Dr. Hongqi Tian

    Founder, Chairman, Chief Executive Officer

    Dr. Hongqi Tian, the founder of Kechow Pharma, has over twenty years of experience in new drug development. During his time at Array Biopharmaceuticals Inc. in the U.S., he successfully developed four new compounds into preclinical and clinical studies. In 2014, he founded Shanghai Kechow Pharma, Inc. The company’s new anti-cancer drug, HL-085, developed with 100% independent intellectual property rights, is regarded as the best of its kind in this field. It is currently undergoing Phase I/II clinical trials simultaneously in China and the U.S. In addition, the drug has applied for more than 80 patents worldwide, with over 40 granted, and has published 40 articles.

Meanwhile, Kechow Pharma has a comprehensive R&D team that integrates discovery, clinical development, and registration. This team works closely and seamlessly together with technical experts in medicinal chemistry, biology, medicine, registration, pharmacovigilance, project management, and more. From the discovery stage to the preclinical and clinical stages, the team brings extensive practical experience in their respective fields. Currently, our growing R&D team consists of nearly 80 scientists and staff based in Shanghai, Beijing, and Tianjin, as well as international clinical and regulatory offices in the United States. Through our U.S.-based international team, we have been able to rapidly expand our international clinical development and regulatory approval operations.